argenx SE operates in the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares argenx SE with three other
companies in this sector in the United States:
Neoleukin Therapeutics Inc
sales of $25.00 million
of which 100%
was Therapeutics For Inflammatory Diseases a),
Bioanalytical Systems, Inc.
Applied Genetic Technologies Corp
argenx SE reported sales of $25.31 million
December of 2018.
decrease of 39.0%
versus 2017, when the company's sales were $41.48 million.
Contributing to the drop in overall sales was the 78.0% decline
in Research and Development Service Fees (F, from $7.52 million to $1.66 million.
There were also decreases in sales in
Upfront Payments (down 55.6% to $10.17 million)
However, these declines were partially offset by the increase in sales of
Milestone Payments (up 22.3% to $13.48 million)